A 2022 clinical trial investigated ELK1 among other potential biomarkers as a distinctive molecular signature of either urothelial bladder cancer (UBC) or upper tract urothelial carcinoma (UTUC) [255]. Here, ELK1 is linked to bladder transitional cell carcinoma.